A detailed history of Nisa Investment Advisors, LLC transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 2,158 shares of COLL stock, worth $86,082. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,158
Previous 2,134 1.12%
Holding current value
$86,082
Previous $82,000 15.85%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$31.36 - $39.99 $752 - $959
24 Added 1.12%
2,158 $69,000
Q1 2024

May 01, 2024

BUY
$31.23 - $40.91 $968 - $1,268
31 Added 1.47%
2,134 $82,000
Q1 2023

May 02, 2023

SELL
$23.0 - $29.88 $7,360 - $9,561
-320 Reduced 13.21%
2,103 $50,000
Q3 2022

Nov 07, 2022

BUY
$15.46 - $20.1 $510 - $663
33 Added 1.38%
2,423 $43,000
Q2 2022

Aug 03, 2022

BUY
$14.22 - $20.88 $27,729 - $40,716
1,950 Added 443.18%
2,390 $42,000
Q1 2022

Apr 29, 2022

SELL
$17.2 - $22.5 $74,974 - $98,077
-4,359 Reduced 90.83%
440 $9,000
Q4 2021

Feb 03, 2022

SELL
$17.5 - $21.35 $55,230 - $67,380
-3,156 Reduced 39.67%
4,799 $86,000
Q3 2021

Oct 18, 2021

BUY
$17.75 - $25.39 $130,196 - $186,235
7,335 Added 1183.06%
7,955 $157,000
Q4 2020

Jan 25, 2021

SELL
$17.83 - $22.29 $44,432 - $55,546
-2,492 Reduced 80.08%
620 $12,000
Q3 2020

Oct 20, 2020

BUY
$15.78 - $20.82 $37,745 - $49,801
2,392 Added 332.22%
3,112 $65,000
Q2 2020

Jul 27, 2020

SELL
$15.49 - $23.51 $2,246 - $3,408
-145 Reduced 16.76%
720 $13,000
Q4 2019

Jan 17, 2020

SELL
$10.7 - $22.24 $81,908 - $170,247
-7,655 Reduced 89.85%
865 $18,000
Q3 2019

Oct 17, 2019

BUY
$10.16 - $13.28 $86,563 - $113,145
8,520 New
8,520 $98,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.36B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.